Is This Dividend Stock a No-Brainer Buy?
It's often said that near-term fluctuations in the stock market are mostly based on noise rather than fundamentals.
Shares of Pfizer (NYSE: PFE) have tumbled 15% year to date even as the S&P 500 index has rallied 7%. This raises the question: Is this recent weakness in the pharmaceutical company a buying opportunity for income investors? Let's discuss Pfizer's fundamentals and valuation to address this question.
Over the course of its nearly 175 years in business, Pfizer has, time and time again, proven itself as an innovative company. In the many decades of corporate history leading up to the launch of its antiviral COVID-19 treatment, dubbed Paxlovid, and its COVID-19 vaccine co-owned with BioNTech (NASDAQ: BNTX), named Comirnaty, Pfizer was involved in critical moments in science. These include deep-tank fermentation that led to the mass production of the antibiotic penicillin and the discovery of citric acid.
Source Fool.com
